| Mr Ashwin Bavisi, | |
|
140 W Lake St, Addison, IL 60101-2720 | |
| (630) 628-6904 | |
| Not Available |
| Full Name | Mr Ashwin Bavisi |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 140 W Lake St, Addison, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861607871 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 051-031246 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Ashwin Bavisi, 140 W Lake St, Addison, IL 60101-2720 Ph: (630) 628-6904 | Mr Ashwin Bavisi, 140 W Lake St, Addison, IL 60101-2720 Ph: (630) 628-6904 |
News Archive
Newswise has recently partnered with the National Cancer Institute (NCI) to create a comprehensive site for cancer research news and experts - the Cancer News Source. NCI and other leaders in cancer research provide the content, creating a site that contains the most up-to-date information directly from the source.
An ophthalmologist at UT Southwestern Medical Center has helped create a convenient device that lets patients who have a degenerative eye disease better track vision changes.
'A Healthier Future: A Strategic Framework for Respiratory Conditions', is a consultation document which sets out a 10-year framework for preventing respiratory disease, and for improving treatment and care for people with respiratory conditions.
Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to late-breaking results from the COMPASS trial presented today in a Hot Line - LBCT Session at ESC Congress1 and published in the NEJM.
Idera Pharmaceuticals, Inc. today announced preliminary results from a Phase 1 clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. In this trial, healthy subjects in five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was well tolerated at all dose levels.
› Verified 5 days ago
Morin Odeesh, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16 E Lake St, Addison, IL 60101 Phone: 630-832-7821 Fax: 630-832-3195 | |
Kimmy Chan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16 E Lake St, Addison, IL 60101 Phone: 630-854-7546 | |
Mary Rae Butler, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 344 E Palmer Ave, Addison, IL 60101 Phone: 630-363-1818 | |
Dr. Mary Ellen Foster, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 220 N Cardinal Ave, Addison, IL 60101 Phone: 630-530-7123 Fax: 630-530-0246 | |
Syed Arshad Makki, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16 E Lake St, Addison, Addison, IL 60101 Phone: 630-832-7821 Fax: 630-832-3195 | |
Irene Panos, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16 E Lake St, Addison, IL 60101 Phone: 630-832-7821 Fax: 630-832-3195 | |
Simon James Staub, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3n471 Meadow Rd, Addison, IL 60101 Phone: 630-456-2253 |